Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ventricular flutter

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Ventricular flutter. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-001905-42 Sponsor Protocol Number: LDLL600.201 Start Date*: 2014-10-23
    Sponsor Name:AOP Oprhan Pharmaceuticals AG
    Full Title: Open-label Two-arm PD and PK Study of Landiolol in Patients with Tachycardic Atrial Fibrillation or Atrial Flutter
    Medical condition: 20 Caucasian patients with tachycardic atrial fibrillation (AF) or atrial flutter (AFL)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10003663 Atrial flutter/ fibrillation LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002210-13 Sponsor Protocol Number: STARC210421 Start Date*: 2022-01-17
    Sponsor Name:The department of cardiac, thoracic and vascular surgery - Odense University Hospital
    Full Title: Post-Operative Atrial Fibrillation after Surgical Aortic Valve Replacement and the influence of HMG-CoA reductase inhibitors
    Medical condition: Trial 2: Condition under investigation: Postoperative atrial fibrillation after surgical aortic valve replacement. In patients no prior usage of statins: 14 days prior surgery to 30days after - Ato...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003660 Atrial fibrillation and flutter LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003455-36 Sponsor Protocol Number: D3190C00005 Start Date*: 2007-12-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-centre, Double-blind, Randomised, Placebo-controlled, Single-dose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion...
    Medical condition: AZD1305 is a novel antiarrhythmic agent being developed for treatment of atrial fibrillation (AF). Potential indications include conversion of AF to sinus rhythm (SR) and maintenance of SR after c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000715-98 Sponsor Protocol Number: EFC5555 Start Date*: 2005-12-28
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A placebo-controlled, double blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with...
    Medical condition: atrial fibrillation/atrial flutter
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003658 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SE (Completed) FI (Completed) CZ (Completed) BE (Completed) NO (Completed) IT (Completed) PT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000823-40 Sponsor Protocol Number: DRI5760 Start Date*: 2005-08-01
    Sponsor Name:Sanofi-Synthelabo-Recherche
    Full Title: Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C 300 or 600 mg for the conversion of atrial fibrillation/flutter
    Medical condition: Atrial fibrillation/flutter
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003658 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001529-18 Sponsor Protocol Number: LGN-VN-003 Start Date*: 2015-08-18
    Sponsor Name:Laguna Pharmaceuticals, Inc.
    Full Title: RESTORE SR: A multi-center, Randomized, double-blind, placebo-controlled study to Evaluate the Safety and efficacy of a single oral dose of vanoxerine for The conversion Of subjects with REcent ons...
    Medical condition: Recent atrial fibrillation (AF) or atrial flutter (AFL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) NL (Ongoing) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002147-91 Sponsor Protocol Number: CV185-030 Start Date*: 2007-05-14
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalv...
    Medical condition: ARRHYTHMIA; THROMBOSIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    9.1 10057613 Thromboembolic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) BE (Completed) FI (Completed) ES (Completed) DK (Completed) HU (Completed) AT (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005844-47 Sponsor Protocol Number: D6580C00010 Start Date*: 2021-05-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants wit...
    Medical condition: Heart Failure with Left Ventricular Ejection Fraction > 40%
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) SK (Completed) CZ (Completed) DK (Completed) BG (Completed) FR (Completed) HU (Completed) PL (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001518-13 Sponsor Protocol Number: 10407 Start Date*: 2018-11-12
    Sponsor Name:Maatschap Cardiologie Zwolle
    Full Title: Comparison between treatment with catheter ablation or anti-arrhythmic drugs (sotalol or combination of verapamil and flecainide) of patients with benign ventricular premature beats and ventricular...
    Medical condition: Premature ventricular beats, ventricular ectopy, ventricle tachycardia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000802-46 Sponsor Protocol Number: D169CC00001 Start Date*: 2018-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur...
    Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-001716-59 Sponsor Protocol Number: D4120C00002 Start Date*: 2011-10-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoi...
    Medical condition: Arrhythmia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10003119 Arrhythmia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2010-019791-73 Sponsor Protocol Number: EFC11405 Start Date*: 2010-07-22
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrill...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) HU (Completed) BE (Prematurely Ended) SK (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) DE (Completed) IT (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002541-11 Sponsor Protocol Number: P170912J Start Date*: 2019-06-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in patients undergoing cardiac surgery
    Medical condition: Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery) will be eligible
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004865 10067824 Prophylaxis against atrial fibrillation LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001766-40 Sponsor Protocol Number: DRI5165 Start Date*: 2004-12-20
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: Placebo controlled double blind dose ranging study of the efficacy and safety of SSR149744C 50, 100, 200, or 300 mg OD, with amiodarone as calibrator for the maintenance of sinus rhythm in patients...
    Medical condition: Atrial fibrillation/flutter
    Disease: Version SOC Term Classification Code Term Level
    7.0 10003658 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) DK (Completed) IT (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000664-31 Sponsor Protocol Number: D169DC00001 Start Date*: 2020-08-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Ac...
    Medical condition: Acute Myocardial Infarction, Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-001292-14 Sponsor Protocol Number: CV029-009 Start Date*: 2022-11-30
    Sponsor Name:MyoKardia, Inc.
    Full Title: A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Le...
    Medical condition: Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000302-12 Sponsor Protocol Number: BUC-CLIN-303 Start Date*: 2016-07-13
    Sponsor Name:ARCA biopharma, Inc.
    Full Title: GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) PL (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002671-34 Sponsor Protocol Number: PI20208430057 Start Date*: 2020-12-04
    Sponsor Name:CHU Amiens-Picardie
    Full Title: Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractlity: an open label prospective randomized study
    Medical condition: septic shock with hypercontractlity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005302-26 Sponsor Protocol Number: DW.0701.005.2020P Start Date*: 2023-01-05
    Sponsor Name:John Paul II Hospital
    Full Title: The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with mid-range ejection fraction
    Medical condition: heart failure with moderately reduced ejection fraction (HFmrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017838-44 Sponsor Protocol Number: CJO-201 Start Date*: 2010-04-21
    Sponsor Name:Sequel Pharmaceuticals, Inc.
    Full Title: A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary Efficacy Study of K201 Oral for the Prevention of Atrial Fibrillation (AF) Recurre...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 12 16:58:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA